YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer

  • Federica Lo Sardo
  • , Claudio Pulito
  • , Andrea Sacconi
  • , Etleva Korita
  • , Marius Sudol
  • , Sabrina Strano
  • , Giovanni Blandino

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Abstract

Lung cancer is the leading cause of cancer-related deaths, worldwide. Non–small cell lung cancer (NSCLC) is the most prevalent lung cancer subtype. YAP and TAZ have been implicated in lung cancer by acting as transcriptional co-activators of oncogenes or as transcriptional co-repressors of tumor suppressor genes. Previously we reported that YAP and TAZ regulate microRNAs expression in NSCLC. Among the set of regulated miRNAs, the oncogenic miR-25, 93, and 106b, clustering within the MCM7 gene were selected for further studies. We firstly identified Transforming Growth Factor-β (TGF-β) Receptor 2 (TGFBR2), a member of the TGF-β signaling, as a target of the miRNA cluster, which exhibited prognostic value because of its tumor suppressor activity. We found that YAP/TAZ-mediated repression of TGFBR2 occurs both: post-transcriptionally through the miR-106b-25 cluster and transcriptionally by engaging the EZH2 epigenetic repressor that we reported here as a novel target gene of YAP/TAZ. Furthermore, we document that YAP/TAZ and EZH2 cooperate in lung tumorigenesis by transcriptionally repressing a specific subset of tumor suppressor genes, including TGFBR2. Our findings point to YAP/TAZ and EZH2 as potential therapeutic targets for NSCLC treatment.

Original languageEnglish
Pages (from-to)51-63
Number of pages13
JournalCancer Letters
Volume500
DOIs
StatePublished - 1 Mar 2021

Keywords

  • Dasatinib
  • Hippo pathway
  • Lung cancer
  • PRC2
  • Tazemetostat

Fingerprint

Dive into the research topics of 'YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this